A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-516.

Publication Type:

Journal Article

Authors:

Backus, L.I.; Boothroyd, D.B.; Phillips, B.R.; Belperio, P.; Halloran, J.; Mole, L.A.

Source:

Clin Gastroenterol Hepatol, Volume 9, Issue 6, p.509-516 (2011)

Keywords:

administration & dosage, Antiviral Agents, California, Carcinoma, co-infection, coinfection, Comorbidity, drug therapy, Female, Genotype, genotype 1, HCV, Health, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Human, Humans, interferon, Interferons, isolation & purification, Laboratories, Male, methods, Middle Aged, Mortality, Patients, pegylated, pegylated interferon, Public Health, Research, Research Support, Ribavirin, Risk, Rna, Survival, Survival Analysis, sustained virologic response, SVR, Treatment Outcome, United States, Veterans, Viral Load, virology

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/21397729

Export Citation:

RIS Format

Top